CD79A and COVID-19: We detected transient rises in XBB.1.5-specific total IgG and IgA and FcγR2a binding responses in both plasma and saliva in 3 of the 4 study participants (Figure 4, B–G), confirming that breakthrough COVID-19 can boost mucosal immunity.